Sheet of COCHET Alexandre

Since 2014 : PU-PH in Biophysics and Nuclear Medicine, Université Bourgogne Europe

2011-2014 : MCU-PH in Biophysics and Nuclear Medicine, Université de Bourgogne

2013: Habilitation à Diriger des Recherches, Université de Bourgogne

2010-2011: “Visiting research fellow”, Peter Mac Callum Cancer Centre, Melbourne, Australie

2007-2011 : Medical specialist, Centre Georges-François Leclerc, Dijon

2009 : PhD, Université de Bourgogne

2005-2007 : Assistant Hospitalo-Universitaire, CHU Dijon

2005 : MD, Université de Bourgogne

2004 : MSc, Université Paul Sabatier, Toulouse

Since 2015 : Head of Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon

Since 2015 : Head of the Service of Nuclear Medicine and NMR spectroscopy, CHU Dijon

Since 2018 : Directeur chargé des Coopérations, Centre Georges-François Leclerc, Dijon

Since 2018 : Responsable Pédagogique de la DFGSM-2, UFR des Sciences de Santé, Université Bourgogne Europe

Since 2024 : Member of the laboratory council of ICMUB, UMR CNRS 6302, University of Burgundy

2020-2022 : Elected member of the administrative board of the University of Burgundy

2018-2022 : Elected member of the administrative board of the UFR des Sciences de Santé, University of Burgundy

2017-2024 : Scientific coordinator of Equipex IMAPPI

2019-2022 : Head of IFTIM team, ImVIA laboratory, University of Burgundy

2016-2018 : Head of pôle 7 « Imagerie médicale et santé », Laboratory Le2i CNRS FRE 2005, University of Burgundy

• Equipex IMAPPI (2012-2024): “Integrated Magnetic resonance And Positron emission tomography in Preclinical Imaging”. Financement PIA 2011, 7,3 M€.
• PREMETHEP : « Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib », PHRC-K national 409 k€. (NCT02847468)
• IMKRUN2 : « A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC », phase 0/1. (NCT02847377)
• ESTROTIMP : « Impact of 18F-FES PET on the Therapeutic Management of Patients With Metastatic Breast Cancer », phase 4. (NCT05486182)
• COMETE: “moleCular radiOtherapy for METastatic Colorectal and gastric cancErs”. Financement FEDER 2023, 7,8 M€

Main publications (2020-2025)

1) Godard F, Oosthoek J, Alexis A, Léo P, Fontaine E, Dahmani M, Houot L, Quermonne M, Cochet A, Drouet C. Estimation of carbon footprint in nuclear medicine: illustration of a french department. Eur J Nucl Med Mol Imaging. 2025 Feb 20. doi: 10.1007/s00259-025-07129-x. Epub ahead of print. PMID: 39976702.

2) Payan N, Presles B, Coutant C, Desmoulins I, Ladoire S, Beltjens F, Brunotte F, Vrigneaud JM, Cochet A. Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer. EJNMMI Res. 2024 Jul 4;14(1):60. doi: 10.1186/s13550-024-01115-4. PMID: 38965124; PMCID: PMC11224181

3) Merlet A, Presles B, Su KH, Salvadori J, Sayah F, Jozi H, Cochet A, Vrigneaud JM. Validation of a discovery MI 4-ring model according to the NEMA NU 2-2018 standards: from Monte Carlo simulations to clinical-like reconstructions. EJNMMI Phys. 2024 Jan 31;11(1):13. doi: 10.1186/s40658-024-00616-4. PMID: 38294624; PMCID: PMC11266333.

4) Cassin J, Walker PM, Blanc J, Asuncion A, Bardet F, Cormier L, Loffroy R, Cochet A. Role of magnetic resonance imaging for preoperative prediction of early biochemical failure in localized prostate cancer. Quant Imaging Med Surg. 2023 Mar 1;13(3):1440-1452. doi: 10.21037/qims-22-472. Epub 2023 Jan 5. PMID: 36915312; PMCID: PMC10006114.

5) Prevot S, Dygaï-Cochet I, Riedinger JM, Vrigneaud JM, Quermonne M, Gallet M, Cochet A. Dealing with dry waste disposal issues associated with  177mLu impurities: a long-term challenge for nuclear medicine departments. EJNMMI Phys. 2023 Jan 9;10(1):3. doi: 10.1186/s40658-023-00524-z. PMID: 36622501; PMCID: PMC9829929.

6) Asuncion A, Walker PM, Bertaut A, Blanc J, Labarre M, Martin E, Bardet F, Cassin J, Cormier L, Crehange G, Loffroy R, Cochet A. Prediction of prostate cancer recurrence after radiation therapy using multiparametric magnetic resonance imaging and spectroscopy: assessment of prognostic factors on pretreatment imaging. Quant Imaging Med Surg. 2022 Dec;12(12):5309-5325. doi: 10.21037/qims-22-184. PMID: 36465820; PMCID: PMC9703104.

7) Payan N, Presles B, Truntzer C, Courcet E, Coutant C, Desmoulins I, Brunotte F, Vrigneaud JM, Cochet A. Critical analysis of the effect of various methodologies to compute breast cancer tumour blood flow-based texture features using first-pass 18F-FDG PET. Phys Med. 2022 Nov;103:98-107. doi: 10.1016/j.ejmp.2022.09.015. Epub 2022 Oct 17. PMID: 36260968.

8) Oudot A, Courteau A, Guillemin M, Vrigneaud JM, Walker PM, Brunotte F, Cochet A, Collin B. [123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study. EJNMMI Res. 2021 Sep 20;11(1):92. doi: 10.1186/s13550-021-00835-1. PMID: 34542689; PMCID: PMC8452816.

9) Nodari G, Popoff R, Riedinger JM, Lopez O, Pellegrinelli J, Dygai-Cochet I, Tabouret-Viaud C, Presles B, Chevallier O, Gehin S, Gallet M, Latournerie M, Manfredi S, Loffroy R, Vrigneaud JM, Cochet A. Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy. EJNMMI Res. 2021 Mar 9;11(1):24. doi: 10.1186/s13550-021-00766-x. PMID: 33687596; PMCID: PMC7943673.

10) Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, Oudot A, Helbling A, Guillemin M, Bonniaud P, Cochet A, Collin B, Bellaye PS. [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [¹⁸F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3058-3074. doi: 10.1007/s00259-021-05209-2. Epub 2021 Feb 13. PMID: 33580818; PMCID: PMC8426306.

11) Courteau A, McGrath J, Walker PM, Pegg R, Martin G, Garipov R, Doughty P, Cochet A, Brunotte F, Vrigneaud JM. Performance Evaluation and Compatibility Studies of a Compact Preclinical Scanner for Simultaneous PET/MR Imaging at 7 Tesla. IEEE Trans Med Imaging. 2021 Jan;40(1):205-217. doi: 10.1109/TMI.2020.3024722. Epub 2020 Dec 29. PMID: 32956042.

12) Payan N, Presles B, Brunotte F, Coutant C, Desmoulins I, Vrigneaud JM, Cochet A. Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1103-1115. doi: 10.1007/s00259-019-04422-4. Epub 2019 Aug 8. PMID: 31396665.

First cycle of medical studies :

Teachiing in PASS and DFGSM-2 (CM, ED)

Head of DFGSM-2 (since 2018)

Masters :

Head of UE M1 « Functional and molecular imaging » (since 2012)

Participation to international masters :

• Innovative drugs
• Health-AI
• Medical Imaging and applications

Third cycle:

Participation to national teaching of DES de Médecine Nucléaire (since 2012)

Participation to DU IA et Santé